<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406821</url>
  </required_header>
  <id_info>
    <org_study_id>SU-10162010-7109</org_study_id>
    <secondary_id>16595</secondary_id>
    <nct_id>NCT01406821</nct_id>
  </id_info>
  <brief_title>Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma</brief_title>
  <official_title>Randomized, Double-blind Clinical Trial of Platelet Rich Plasma for Treatment of Acute and Chronic Patellar Tendinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Platelet rich plasma has been used in previous studies to stimulate faster healing of torn&#xD;
      ligaments and tendons in order to help reduce pain and restore normal function. This study&#xD;
      aims to prove that non-operative treatment of acute and chronic ligament and tendon injuries&#xD;
      with platelet rich plasma will reduce the time needed for participants to heal these injuries&#xD;
      and restore function.&#xD;
&#xD;
      We are currently enrolling patients with PATELLAR TENDON INJURIES in the KNEE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-procedure diagnosis: The appropriate clinical evaluation will be dictated by the&#xD;
      examining physician. Minimal pre-procedure studies will include plain radiographs and MRI.&#xD;
      All patients will complete a pretreatment questionnaire.&#xD;
&#xD;
      Patients will be randomized and blinded to a treatment regimen.&#xD;
&#xD;
      Method of randomization: Some of the participating subjects will receive platelet rich plasma&#xD;
      and others will receive a saline injection. The platelet rich plasma experimental group will&#xD;
      have up to 50cc of whole blood collected via venipuncture and prepared using the standard PRP&#xD;
      protocol.&#xD;
&#xD;
      To blind the control group these patients will have a simulated needle stick and&#xD;
      approximately 10 ml (2 teaspoons) of blood will be drawn. No blood will be given back to the&#xD;
      patient. For those in the control group their ligament or tendon will be stimulated with dry&#xD;
      needling (moving a needle up and down in the tendon, without injection). Patients in the PRP&#xD;
      treatment group will also have dry needling, plus the PRP will be injected into the tendon as&#xD;
      well.&#xD;
&#xD;
      Platelet rich plasma injections have an equivalent risk profile to routine injections. Those&#xD;
      potential risks include skin discoloration, pain at injection site, superficial or deep&#xD;
      infection, no relief of symptoms, worsening of symptoms, and damage to nerve and blood&#xD;
      vessels. Potential benefits include significant improvement in symptoms and reduction in time&#xD;
      for return to function.&#xD;
&#xD;
      Post injection activity: All patients will use crutches for 24-48 hours after injection. All&#xD;
      patients will have physical therapy two times a week according to a standardized protocol.&#xD;
&#xD;
      Follow up at the clinic for all patients will be every 3 weeks from weeks 1-12. All patients&#xD;
      will fill out an injury location specific questionnaire, Tegner Activity Scale, short&#xD;
      form-12, and visual analog scale for pain, among others. Additional follow-up will be done at&#xD;
      6 months, 1 year and 2 years. All radiographic studies will be read by a radiologist blinded&#xD;
      to the study groups.&#xD;
&#xD;
      The primary endpoint for all patients in the study will be twelve weeks. Secondary enpoints&#xD;
      are 6 months, 1 year and 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported improvement in symptoms at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in patellar tendinosis by MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Dry needling</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet-rich plasma (PRP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood will be drawn, and platelet-rich plasma will be injected into the tendon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided platelet-rich-plasma (PRP) injection</intervention_name>
    <description>Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.</description>
    <arm_group_label>Platelet-rich plasma (PRP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided dry needling</intervention_name>
    <description>Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.</description>
    <arm_group_label>Dry needling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Acute or chronic ligament or tendon injuries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  children,&#xD;
&#xD;
          -  other injuries that require surgical intervention,&#xD;
&#xD;
          -  associated fractures,&#xD;
&#xD;
          -  systemic disease resulting in an immunocompromised state affecting ability to heal&#xD;
             soft tissues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Christina Herrero</last_name>
    <role>Study Director</role>
    <affiliation>New York University Langone Orthopedic Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Jason L. Dragoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Orthopedic Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jason L. Dragoo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PRP</keyword>
  <keyword>platelet-rich-plasma</keyword>
  <keyword>platelet</keyword>
  <keyword>tendinosis</keyword>
  <keyword>tendinitis</keyword>
  <keyword>tendonitis</keyword>
  <keyword>tendinopathy</keyword>
  <keyword>enthesopathy</keyword>
  <keyword>muscle</keyword>
  <keyword>sport</keyword>
  <keyword>tendon</keyword>
  <keyword>patella</keyword>
  <keyword>patellar tendon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

